Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

Chemical Formula: -

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Associated Therapies: -

Clinical Trials

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

Phase 4

Conditions: Rheumatoid Arthritis

Interventions: Drug: H.P. Acthar gel

First Posted Date: 2017-03-17

Last Posted Date: 2017-03-17

Lead Sponsor: Iraj Sabahi Research Inc.

Target Recruit Count: 30

Registration Number: NCT03082573

Locations: 🇺🇸
Iraj Sabahi Research Inc, Turlock, California, United States

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Acthar
Drug: Placebo

First Posted Date: 2017-03-03

Last Posted Date: 2020-10-14

Lead Sponsor: Mallinckrodt

Target Recruit Count: 143

Registration Number: NCT03068754

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 66 locations

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

Phase 4

Conditions: Uveitis, Posterior
Vasculitis Retinal

Interventions: Drug: H.P. ACTHAR GEL

First Posted Date: 2017-03-01

Last Posted Date: 2019-09-12

Lead Sponsor: Ocular Immunology and Uveitis Foundation

Target Recruit Count: 40

Registration Number: NCT03066869

Locations: 🇺🇸
Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts, United States

Adrenocorticotropic Hormone in Membranous Nephropathy

Phase 4

Completed

Conditions: Membranous Nephropathy

Interventions: Drug: ACTHar

First Posted Date: 2017-01-20

Last Posted Date: 2022-08-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 5

Registration Number: NCT03025828

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

Phase 4

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: ACTHar

First Posted Date: 2017-01-13

Last Posted Date: 2024-05-16

Lead Sponsor: University of Chicago

Target Recruit Count: 5

Registration Number: NCT03021317

Availability Study of ACTH to Treat Children SRNS/SDNS

Not Applicable

Conditions: Proteinuria

Interventions: Drug: ACTH

First Posted Date: 2016-11-23

Last Posted Date: 2016-11-23

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 42

Registration Number: NCT02972346

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

Phase 4

Terminated

Conditions: Uveitis

Interventions: Drug: Acthar

First Posted Date: 2016-05-12

Last Posted Date: 2018-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 2

Registration Number: NCT02769702

Locations: 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

Phase 3

Active, not recruiting

Conditions: FSGS

Interventions: Drug: Acthar

First Posted Date: 2016-02-17

Last Posted Date: 2024-04-08

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 20

Registration Number: NCT02683889

Locations: 🇺🇸
Medstar Georgetown Transplant Institute, Washington, District of Columbia, United States

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Acthar

First Posted Date: 2015-09-04

Last Posted Date: 2024-05-07

Lead Sponsor: Veena Ranganath, MD, MS

Target Recruit Count: 40

Registration Number: NCT02541955

Locations: 🇺🇸
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, United States

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

Not Applicable

Conditions: Rheumatoid Arthritis

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2015-05-05

Last Posted Date: 2015-05-05

Lead Sponsor: Ronald J. Rapoport, MD

Target Recruit Count: 10

Registration Number: NCT02434757

Locations: 🇺🇸
Phase III Clinical Research, Fall River, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy